RE:RE:Phil & Montel on CityTV Toronto this morningI have had intensive discussions with a close associate who, for 25 yrs, was a senior exec with Sanofi aquisitions. This is what the sum of the discussion was ; " If a product relies on the "User Pay" business model, it will remain a fringe market seller. In Helius's case, the treatment planl is a $30,000 user pay plan.
A) How much of the market is
able to pay ?
B) Although Health Canada approved, the FDA did not (largest market). Has confidence been lost to a large percentage of the CDN market as a result of FDA failure? I don't think I would be quick to spend $30K under that cloud.
HSM may still be a trade
IF and
WHEN a re-submission to the FDA is timelined (with no guarantee of approval) however ;
A) The business model is still a "User Pay" which greatly reduces the revenue potential
B) An
"if n' when" approach to an investment strategy, generally results in disappointment
"Don't invest on "faith"....invest on "facts"......
stockhunter20001 wrote:
That's good! Now they are building the momentum in Canada. And hopefully they will get CE approved soon.
After all, I like how they managed to flip the bad news quickly, with this marketing effort.
They restored my faith in them again!